Login
MacroGenics NASDAQ: MGNX
We are a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, autoimmune disorders and infectious diseases
| Name | MacroGenics |
| Ticker | MGNX |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Price | 22.59 |
| 52W Low/High | 4.28 / 31.60 |
| Market cap | 1.2 B |
| 1Y Total Return |
133.49%
Strong |
| 1Y Volatility |
148.13%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
We are a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, autoimmune disorders and infectious diseases
Details
| Ticker | MGNX |
| Name | MacroGenics |
| ISIN | |
| CUSIP | 556099109 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 12/3/20
| Close Price | 22.59 |
| 52W Low/High | 4.28 / 31.60 |
| Market cap | 1.2 B |
| 1Y Total Return |
133.49%
Strong |
| 1Y Volatility |
148.13%
High Risk |
| Beta | 3.17 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -204.2% |
| Cash from Op. / Cur. Liabilities | -2.88 |
| Diluted Earnings / Share | -3.13 |
| ROE | - |
| ROIC | -121.6% |
| Price / Revenue | 15.9 |
| Price / Book | 4.2 |
| Price / CF | -8.5 |
| Current Ratio | 6.2 |
| Cur.Liabilities / Tot.Liabilities | 0.6 |
| Financial Leverage | 0.10 |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
77
|
55
|
197
|
10
|
95
|
98
|
|
| Gross Profit |
77
|
55
|
197
|
10
|
95
|
98
|
|
| R&D |
203
|
190
|
183
|
139
|
121
|
88
|
|
| EBITDA |
-146
|
-154
|
-14
|
-152
|
-45
|
-9
|
|
| Operating Income |
-168
|
-180
|
-25
|
-162
|
-53
|
-11
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
54
|
49
|
42
|
37
|
35
|
33
|
|
| EPS exc. Extra |
-3.13
|
-3.61
|
-0.22
|
-4.50
|
-1.61
|
-0.44
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
374
|
351
|
355
|
242
|
340
|
384
|
|
| Cash, Eq & Invt ShortTerm |
281
|
254
|
260
|
204
|
311
|
366
|
|
| Total Current Assets |
310
|
276
|
286
|
209
|
316
|
370
|
|
| Total Non-Current Assets |
64
|
75
|
70
|
32
|
24
|
14
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
83
|
96
|
73
|
52
|
40
|
45
|
|
| Total Current Liabilities |
50
|
58
|
48
|
32
|
22
|
22
|
|
| Long Term Debt |
33
|
39
|
25
|
20
|
18
|
22
|
|
| Shareholder equity |
292
|
255
|
283
|
189
|
300
|
339
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-144
|
-123
|
-14
|
-126
|
-40
|
-10
|
|
| Depreciation |
12
|
12
|
7
|
8
|
7
|
2
|
|
| Cash from Investing |
16
|
-42
|
20
|
71
|
-218
|
-8
|
|
| Capex |
4
|
4
|
35
|
20
|
13
|
8
|
|
| Cash from Financing |
174
|
120
|
105
|
35
|
2
|
204
|
|
| Stock Issued |
176
|
120
|
105
|
35
|
2
|
204
|
|
| Debt (LT) Issued |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Free Cash Flow |
-152
|
-206
|
23
|
-55
|
-260
|
-26
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
6.2
|
4.8
|
5.9
|
6.5
|
14.3
|
16.6
|
|
| Financial Leverage D/E |
0.10
|
0.12
|
0.00
|
0.00
|
0.00
|
0.00
|
|
| Return on Capital Avg |
-121.6%
|
-136.8%
|
-18.8%
|
-98.1%
|
-51.2%
|
-
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available